SANOFI
761 institutions still hold SANOFI as of Q2 2026. Tracked across SEC 13F-HR filings, with insider and 13D/G activity surfaced alongside.
Sanofi SA (SNY, CUSIP 80105N105) entered Q1 2026 with $9.7B of institutional 13F value across the broad holder universe, reflecting the firm's standing as a large-cap European healthcare anchor — a diversified pharmaceutical company with vaccine, consumer healthcare, and specialty medicine franchises. With no single top-holder dominating at the extreme concentrations typical of earlier-stage biotechs, Sanofi's institutional book is spread across diversified healthcare, European equity, and large-cap value mandates rather than concentrated in biotech conviction names. The $9.7B figure represents a floor (the number of institutional accounts filing 13Fs in the U.S. with Sanofi exposure), not the full global picture — domestic U.S. institutional sleeves are the relevant read for this data set. For retail investors, SNY's institutional backing through passive large-cap Europe vehicles and healthcare-dedicated active strategies signals broad confidence in the clinical pipeline without any one manager driving the narrative.
Top holders
Sorted by position value. Source: SEC EDGAR 13F-HR filings.